Pancreatic Cancer Research

ResearcherTokushima UniversityActive in the last 2 years

Yu Saito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6349-1669; OpenAlex author ID A5054204391. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 8

  1. Outcomes of remnant pancreatic resection for recurrent pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4026151/v1↗
  2. Malnutrition by European Society for Clinical Nutrition and Metabolism criteria predicts prognosis in patients with gastrointestinal and hepatobiliary-pancreat… Co-author DOI 10.1016/j.clnesp.2021.01.023↗
  3. Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02205-6↗
  4. Value of the CRP-albumin ratio in patients with resectable pancreatic cancer. Co-author DOI 10.2152/jmi.68.244↗
  5. Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer. Co-author DOI 10.2152/jmi.68.342↗
  6. Impact of phase angle on postoperative prognosis in patients with gastrointestinal and hepatobiliary-pancreatic cancer. Co-author DOI 10.1016/j.nut.2020.110891↗
  7. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10147-013-0529-6↗
  8. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. Last author DOI 10.1007/s10147-011-0246-y↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuo Shimada · 8 shared papers, 2011–2024 · strength 0.91
  2. Tetsuya Ikemoto · 6 shared papers, 2011–2024 · strength 0.70
  3. Shinichiro Yamada · 3 shared papers, 2021–2024 · strength 0.50
  4. Masaaki Nishi · 3 shared papers, 2020–2021 · strength 0.35
  5. Yusuke Arakawa · 2 shared papers, 2021 · strength 0.27
  6. Hiroki Teraoku · 1 shared paper, 2024 · strength 0.23
  7. Takayuki Noma · 1 shared paper, 2024 · strength 0.23
  8. Sonoko Yasui‐Yamada · 2 shared papers, 2020–2021 · strength 0.22
  9. Nozomi Aotani · 2 shared papers, 2020–2021 · strength 0.22
  10. Yasuhiro Hamada · 2 shared papers, 2020–2021 · strength 0.22
  11. Tohru Utsunomiya · 2 shared papers, 2011–2014 · strength 0.07
  12. Shuichi Iwahashi · 2 shared papers, 2011–2014 · strength 0.07
  13. Koji Sugimoto · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.